These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11251884)

  • 1. Autoantibody to the leucine zipper region of 52 kDa Ro/SSA binds native 60 kDa Ro/SSA: identification of a tertiary epitope with components from 60 kDa Ro/SSA and 52 kDa Ro/SSA.
    Kurien BT; Chambers TL; Thomas PY; Frank MB; Scofield RH
    Scand J Immunol; 2001 Mar; 53(3):268-76. PubMed ID: 11251884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibody responses to the "native" 52-kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus, and Sjogren's syndrome.
    Buyon JP; Slade SG; Reveille JD; Hamel JC; Chan EK
    J Immunol; 1994 Apr; 152(7):3675-84. PubMed ID: 7511655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope mapping of the 52-kD Ro/SSA autoantigen.
    Frank MB; Itoh K; McCubbin V
    Clin Exp Immunol; 1994 Mar; 95(3):390-6. PubMed ID: 8137537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human anti-Ro autoantibodies bind peptides accessible to the surface of the native Ro autoantigen.
    Huang SC; Yu H; Scofield RH; Harley JB
    Scand J Immunol; 1995 Mar; 41(3):220-8. PubMed ID: 7532872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies to the Ro/SSA antigen are conformation dependent. I: Anti-60 kD antibodies are mainly directed to the native protein; anti-52 kD antibodies are mainly directed to the denatured protein.
    Itoh Y; Reichlin M
    Autoimmunity; 1992; 14(1):57-65. PubMed ID: 1284379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins.
    Scofield RH; Farris AD; Horsfall AC; Harley JB
    Arthritis Rheum; 1999 Feb; 42(2):199-209. PubMed ID: 10025913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kDa Ro(SSA) proteins.
    McCauliffe DP; Yin H; Wang LX; Lucas L
    J Rheumatol; 1994 Jun; 21(6):1073-80. PubMed ID: 7523671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies to the Ro/SSA autoantigen are conformation dependent. II: Antibodies to the denatured form of 52 kD Ro/SSA are a cross reacting subset of antibodies to the native 60 kD Ro/SSA molecule.
    Itoh Y; Itoh K; Frank MB; Reichlin M
    Autoimmunity; 1992; 14(2):89-95. PubMed ID: 1303684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-translational modifications of the major linear epitope 169-190aa of Ro60 kDa autoantigen alter the autoantibody binding.
    Terzoglou AG; Routsias JG; Moutsopoulos HM; Tzioufas AG
    Clin Exp Immunol; 2006 Oct; 146(1):60-5. PubMed ID: 16968399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with peptides from 60 kDa Ro in diverse mouse strains.
    Scofield RH; Pierce PG; James JA; Kaufman KM; Kurien BT
    Scand J Immunol; 2002 Nov; 56(5):477-83. PubMed ID: 12410797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoepitopes of the 52-kd SS-A/Ro molecule.
    Kato T; Sasakawa H; Suzuki S; Shirako M; Tashiro F; Nishioka K; Yamamoto K
    Arthritis Rheum; 1995 Jul; 38(7):990-8. PubMed ID: 7541994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Zn2+ binding domain of the human Ro 52 kDa protein is a target for conformation-dependent autoantibodies.
    Pourmand N; Pettersson I
    J Autoimmun; 1998 Feb; 11(1):11-7. PubMed ID: 9480719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivity with dichotomous determinants of Ro 60 stratifies autoantibody responses in lupus and primary Sjögren's syndrome.
    Reed JH; Dudek NL; Osborne SE; Kaufman KM; Jackson MW; Purcell AW; Gordon TP
    Arthritis Rheum; 2010 May; 62(5):1448-56. PubMed ID: 20131295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can B cell epitopes of 60 kDa Ro distinguish systemic lupus erythematosus from Sjögren's syndrome?
    Scofield AN; Kurien BT; Gordon TP; Scofield RH
    Lupus; 2001; 10(8):547-53. PubMed ID: 11530996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural differences between the human and mouse 52-kD Ro autoantigens associated with poorly conserved autoantibody activity across species.
    Keech CL; Gordon TP; McCluskey J
    Clin Exp Immunol; 1996 May; 104(2):255-63. PubMed ID: 8625517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study.
    Tzioufas AG; Wassmuth R; Dafni UG; Guialis A; Haga HJ; Isenberg DA; Jonsson R; Kalden JR; Kiener H; Sakarellos C; Smolen JS; Sutcliffe N; Vitali C; Yiannaki E; Moutsopoulos HM
    Ann Rheum Dis; 2002 May; 61(5):398-404. PubMed ID: 11959762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A shared idiotype among human anti-Ro/SSA autoantibodies.
    Gaither KK; Harley JB
    J Exp Med; 1989 May; 169(5):1583-8. PubMed ID: 2469761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The recognition of human 60-kDa Ro ribonucleoprotein particles by antibodies associated with cutaneous lupus and neonatal lupus.
    Lee LA; Alvarez K; Gross T; Harley JB
    J Invest Dermatol; 1996 Aug; 107(2):225-8. PubMed ID: 8757767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein.
    Stathopoulou EA; Routsias JG; Stea EA; Moutsopoulos HM; Tzioufas AG
    Clin Exp Immunol; 2005 Jul; 141(1):148-54. PubMed ID: 15958081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis of the SSA/Ro antigens and the clinical significance of their autoantibodies.
    Ben-Chetrit E
    Br J Rheumatol; 1993 May; 32(5):396-402. PubMed ID: 8495261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.